Durability of the Treatment Effects of an 8-Week Self-administered Home-Based Virtual Reality Program for Chronic Low Back Pain: 6-Month Follow-up Study of a Randomized Clinical Trial.


Journal

Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882

Informations de publication

Date de publication:
25 05 2022
Historique:
received: 22 02 2022
accepted: 26 04 2022
revised: 22 03 2022
entrez: 25 5 2022
pubmed: 26 5 2022
medline: 28 5 2022
Statut: epublish

Résumé

We previously reported the efficacy of an 8-week home-based therapeutic immersive virtual reality (VR) program in a double-blind randomized placebo-controlled study. Community-based adults with self-reported chronic low back pain were randomized 1:1 to receive either (1) a 56-day immersive therapeutic pain relief skills VR program (EaseVRx) or (2) a 56-day sham VR program. Immediate posttreatment results revealed the superiority of therapeutic VR over sham VR for reducing pain intensity; pain-related interference with activity, mood, and stress (but not sleep); physical function; and sleep disturbance. At 3 months posttreatment, therapeutic VR maintained superiority for reducing pain intensity and pain-related interference with activity, stress, and sleep (new finding). This study assessed between-group and within-group treatment effects 6 months posttreatment to determine the extended efficacy, magnitude of efficacy, and clinical importance of home-based therapeutic VR. E-surveys were deployed at pretreatment, end-of-treatment, and posttreatment months 1, 2, 3, and 6. Self-reported data for 188 participants were analyzed in a mixed-model framework using a marginal model to allow for correlated responses across the repeated measures. Primary outcomes were pain intensity and pain-related interference with activity, mood, stress, and sleep at 6 months posttreatment. Secondary outcomes were Patient-Reported Outcome Measurement Information System (PROMIS) sleep disturbance and physical function. Therapeutic VR maintained significant and clinically meaningful effects 6 months posttreatment and remained superior to sham VR for reducing pain intensity and pain-related interference with activity, stress, and sleep (d Our 8-week home-based VR pain management program caused important reductions in pain intensity and interference up to 6 months after treatment. Additional studies are needed in diverse samples. ClinicalTrials.gov NCT04415177; https://clinicaltrials.gov/ct2/show/NCT04415177. RR2-10.2196/25291.

Sections du résumé

BACKGROUND
We previously reported the efficacy of an 8-week home-based therapeutic immersive virtual reality (VR) program in a double-blind randomized placebo-controlled study. Community-based adults with self-reported chronic low back pain were randomized 1:1 to receive either (1) a 56-day immersive therapeutic pain relief skills VR program (EaseVRx) or (2) a 56-day sham VR program. Immediate posttreatment results revealed the superiority of therapeutic VR over sham VR for reducing pain intensity; pain-related interference with activity, mood, and stress (but not sleep); physical function; and sleep disturbance. At 3 months posttreatment, therapeutic VR maintained superiority for reducing pain intensity and pain-related interference with activity, stress, and sleep (new finding).
OBJECTIVE
This study assessed between-group and within-group treatment effects 6 months posttreatment to determine the extended efficacy, magnitude of efficacy, and clinical importance of home-based therapeutic VR.
METHODS
E-surveys were deployed at pretreatment, end-of-treatment, and posttreatment months 1, 2, 3, and 6. Self-reported data for 188 participants were analyzed in a mixed-model framework using a marginal model to allow for correlated responses across the repeated measures. Primary outcomes were pain intensity and pain-related interference with activity, mood, stress, and sleep at 6 months posttreatment. Secondary outcomes were Patient-Reported Outcome Measurement Information System (PROMIS) sleep disturbance and physical function.
RESULTS
Therapeutic VR maintained significant and clinically meaningful effects 6 months posttreatment and remained superior to sham VR for reducing pain intensity and pain-related interference with activity, stress, and sleep (d
CONCLUSIONS
Our 8-week home-based VR pain management program caused important reductions in pain intensity and interference up to 6 months after treatment. Additional studies are needed in diverse samples.
TRIAL REGISTRATION
ClinicalTrials.gov NCT04415177; https://clinicaltrials.gov/ct2/show/NCT04415177.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
RR2-10.2196/25291.

Identifiants

pubmed: 35612905
pii: v24i5e37480
doi: 10.2196/37480
pmc: PMC9177046
doi:

Banques de données

ClinicalTrials.gov
['NCT04415177']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

e37480

Commentaires et corrections

Type : ErratumIn

Informations de copyright

©Laura Garcia, Brandon Birckhead, Parthasarathy Krishnamurthy, Ian Mackey, Josh Sackman, Vafi Salmasi, Robert Louis, Carina Castro, Roselani Maddox, Todd Maddox, Beth D Darnall. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 25.05.2022.

Références

J Pain. 2015 Feb;16(2):153-63
pubmed: 25463701
Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:191-211
pubmed: 30216744
Arthritis Res Ther. 2011;13(5):R147
pubmed: 21914216
Pain. 2016 Dec;157(12):2766-2772
pubmed: 27755279
J Pain Res. 2019 Jul 03;12:2053-2085
pubmed: 31308733
J Pain. 2022 May;23(5):822-840
pubmed: 34902548
Behav Sleep Med. 2011 Dec 28;10(1):6-24
pubmed: 22250775
Pain Med. 2015 Nov;16(11):2152-61
pubmed: 26257151
J Appl Meas. 2010;11(3):304-14
pubmed: 20847477
Multivariate Behav Res. 2019 Jan-Feb;54(1):85-99
pubmed: 30235003
JMIR Form Res. 2020 Jul 7;4(7):e17293
pubmed: 32374272
Front Psychol. 2013 Nov 26;4:863
pubmed: 24324449
Pain. 2009 Dec;146(3):238-244
pubmed: 19836888
J Med Internet Res. 2021 Feb 22;23(2):e26292
pubmed: 33484240
Pain. 2010 Jun;149(3):435-443
pubmed: 20188472
PLoS One. 2019 Aug 14;14(8):e0219115
pubmed: 31412029
Front Psychol. 2018 Dec 20;9:2508
pubmed: 30618938
JMIR Res Protoc. 2021 Feb 12;10(2):e27652
pubmed: 33577465
Int J Environ Res Public Health. 2021 Nov 11;18(22):
pubmed: 34831562
JMIR Ment Health. 2019 Jan 31;6(1):e11973
pubmed: 30702436
Pain Pract. 2020 Jul;20(6):656-675
pubmed: 32196892
PLoS One. 2017 May 30;12(5):e0178071
pubmed: 28557991

Auteurs

Laura Garcia (L)

AppliedVR, Van Nuys, CA, United States.

Brandon Birckhead (B)

Johns Hopkins School of Medicine, Baltimore, MD, United States.

Parthasarathy Krishnamurthy (P)

University of Houston, Houston, TX, United States.

Ian Mackey (I)

AppliedVR, Van Nuys, CA, United States.

Josh Sackman (J)

AppliedVR, Van Nuys, CA, United States.

Vafi Salmasi (V)

Stanford University School of Medicine, Palo Alto, CA, United States.

Robert Louis (R)

Hoag Memorial Hospital, Newport Beach, CA, United States.

Carina Castro (C)

AppliedVR, Van Nuys, CA, United States.

Roselani Maddox (R)

AppliedVR, Van Nuys, CA, United States.

Todd Maddox (T)

AppliedVR, Van Nuys, CA, United States.

Beth D Darnall (BD)

Stanford School of Medicine, Palo Alto, CA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH